<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971007</url>
  </required_header>
  <id_info>
    <org_study_id>MB-70005</org_study_id>
    <nct_id>NCT02971007</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)</brief_title>
  <official_title>A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy
      of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the
      treatment of moderate to severe VVC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy
      of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the
      treatment of moderate to severe VVC.

      Approximately 75 women with moderate to severe VVC will be randomized to 1 of 3 treatment
      groups (200 mg CAMB, 400 mg CAMB, or fluconazole) to achieve approximately 25 subjects in
      each group. The primary objective of this study is to evaluate the safety of 200 mg and 400
      mg doses of oral CAMB for 5 days compared with a single 150 mg dose of oral fluconazole in
      subjects with moderate to severe VVC. The secondary efficacy objectives of this study
      included the clinical cure rate, mycology eradication and responder outcome. Tertiary
      objectives include pharmacokinetics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>12 days</time_frame>
    <description>Safety assessments will include clinical laboratory assessments (including serum chemistry, hematology, and urinalysis), vital signs, ECGs, both complete and symptom-based physical examinations, prior and concomitant medication reporting, and adverse event reporting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 days</time_frame>
    <description>Resolution of the VVC signs and symptoms that were present at baseline without further antifungal treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 days</time_frame>
    <description>Assessment of culture verified VVC infections</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Day 4</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration time curve (AUC)</measure>
    <time_frame>Day 4</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Vulvovaginitis</condition>
  <condition>Yeast Infection</condition>
  <condition>Yeast Infection Vaginal</condition>
  <condition>Candidiasis, Vulvovaginal</condition>
  <arm_group>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg CAMB (MAT2203) Oral Amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg CAMB (MAT2203) Oral Amphotericin B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluconazole Diflucan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Encochleated Amphotericin B (CAMB)</intervention_name>
    <description>lipid-crystal nano-particle formulation amphotericin B</description>
    <arm_group_label>CAMB 200 mg</arm_group_label>
    <arm_group_label>CAMB 400 mg</arm_group_label>
    <other_name>MAT2203</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <arm_group_label>Fluconazole 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Informed consent

        Clinical diagnosis of moderate to severe VVC

        Negative pregnancy test

        Vaginal pH less than 4.5

        Key Exclusion Criteria:

        Has an intolerance or hypersensitivity to any amphotericin B (AMB) product, or to azole
        antifungal drugs

        Receiving antifungal therapy unrelated to VVC or has evidence of systemic fungal
        infections requiring antifungal therapy

        Has received treatment for VVC within the past 30 days or has experienced 4 or more
        episodes of VVC in the past 12 months

        Has another cause of vulvovaginitis

        Has other urogenital infection(s) that would potentially alter their response to disease

        Has another vaginal or vulvar condition that would confound the interpretation of clinical
        response

        Has significant laboratory abnormality at screening

        Has any known azole-resistant Candida infection;

        Has any other condition the Investigator believes would interfere with the subject's
        ability to provide informed consent, comply with study instructions, or puts the subject
        at undue risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Kling</last_name>
    <role>Study Director</role>
    <affiliation>Matinas BioPharma Nanotechnologies, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Douglas Kling</last_name>
    <phone>(908) 240-2005</phone>
    <email>dkling@matinasbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Osimo</last_name>
      <phone>213-413-2500</phone>
      <email>nicole.osimo@nritrials.com</email>
    </contact>
    <investigator>
      <last_name>Juan Pablo Frias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida - Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariem del Rio</last_name>
      <phone>813-870-1292</phone>
      <phone_ext>129</phone_ext>
      <email>mdelrio@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Sarah Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Vernon Clinical Research - Wake Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willisha Johnson</last_name>
      <phone>404-843-4400</phone>
      <email>wjohnson@mtvcr.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Blank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProHEALTH Care Associates, LLC - Suffolk OB-GYN</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Hurst</last_name>
      <phone>631-656-4060</phone>
      <email>mhurst@prohealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Lance Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Widmer</last_name>
      <phone>513-579-9911</phone>
      <phone_ext>2705</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jo Perez-Jenkins</last_name>
      <phone>210-949-0122</phone>
      <email>mjenkins@cttexas.com</email>
    </contact>
    <investigator>
      <last_name>Douglas S Denham, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tidewater Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Rusch</last_name>
      <phone>757-471-3375</phone>
      <phone_ext>111</phone_ext>
      <email>tcrrusch@cox.net</email>
    </contact>
    <investigator>
      <last_name>Franklin Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>November 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
